How to buy Seres Therapeutics (MCRB) stock

Seres Therapeutics, Inc is a biotechnology business based in the US. Seres Therapeutics shares (MCRB) are listed on the NASDAQ and all prices are listed in US Dollars. Seres Therapeutics employs 155 staff and has a trailing 12-month revenue of around 0.00.

Seres Therapeutics stock price (NASDAQ: MCRB)

Use our graph to track the performance of MCRB stocks over time.

Seres Therapeutics shares at a glance

• Key figures

Information last updated 2021-07-23.

Latest market close	$21.11
52-week range	$3.67 - $38.50
50-day moving average	$20.79
200-day moving average	$21.81
Wall St. target price	$36.57
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.87

Buy Seres Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Seres Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Seres Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Seres Therapeutics price performance over time

Historical closes compared with the close of $21.11 from 2021-05-28

1 week (2021-07-16)	N/A
1 month (2021-06-25)	-10.44%
3 months (2021-04-27)	-0.38%
6 months (2021-01-23)	N/A

1 year (2020-07-23)	N/A
2 years (2019-07-23)	N/A
3 years (2018-07-23)	N/A
5 years (2016-07-23)	N/A

Seres Therapeutics financials

Revenue TTM	$30.7 million
Gross profit TTM	$-57,355,000
Return on assets TTM	-31.16%
Return on equity TTM	-255.22%
Profit margin	0%
Book value	$1.57
Market capitalisation	$677.5 million

TTM: trailing 12 months

Shorting Seres Therapeutics shares

There are currently 6.3 million Seres Therapeutics shares held short by investors – that's known as Seres Therapeutics's "short interest". This figure is 7.5% down from 6.8 million last month.

There are a few different ways that this level of interest in shorting Seres Therapeutics shares can be evaluated.

Seres Therapeutics's "short interest ratio" (SIR)

Seres Therapeutics's "short interest ratio" (SIR) is the quantity of Seres Therapeutics shares currently shorted divided by the average quantity of Seres Therapeutics shares traded daily (recently around 889714.80959097). Seres Therapeutics's SIR currently stands at 7.09. In other words for every 100,000 Seres Therapeutics shares traded daily on the market, roughly 7090 shares are currently held short.

However Seres Therapeutics's short interest can also be evaluated against the total number of Seres Therapeutics shares, or, against the total number of tradable Seres Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Seres Therapeutics's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Seres Therapeutics shares in existence, roughly 70 shares are currently held short) or 0.0943% of the tradable shares (for every 100,000 tradable Seres Therapeutics shares, roughly 94 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Seres Therapeutics.

Find out more about how you can short Seres Therapeutics stock.

Seres Therapeutics share dividends

We're not expecting Seres Therapeutics to pay a dividend over the next 12 months.

Seres Therapeutics share price volatility

Over the last 12 months, Seres Therapeutics's shares have ranged in value from as little as $3.67 up to $38.5. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Seres Therapeutics's is 3.9113. This would suggest that Seres Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Seres Therapeutics overview

Seres Therapeutics, Inc. , a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb clinical trial to treat ulcerative colitis; SER-401, which is in Phase Ib clinical trial for use with checkpoint inhibitors in patients with metastatic melanoma; and SER-301 that is in the Phase 1b clinical trial for the treatment of inflammatory bowel disease. In addition, the company engages in the development of SER-262 to treat an initial recurrence of CDI; and SER-155, a cultivated bacteria microbiome drug designed to prevent mortality due to gastrointestinal infections, bacteremia, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center.

Frequently asked questions

What percentage of Seres Therapeutics is owned by insiders or institutions?
Currently 9.067% of Seres Therapeutics shares are held by insiders and 94.719% by institutions. How many people work for Seres Therapeutics?
Latest data suggests 155 work at Seres Therapeutics. When does the fiscal year end for Seres Therapeutics?
Seres Therapeutics's fiscal year ends in December. Where is Seres Therapeutics based?
Seres Therapeutics's address is: 200 Sidney Street, Cambridge, MA, United States, 02139 What is Seres Therapeutics's ISIN number?
Seres Therapeutics's international securities identification number is: US81750R1023 What is Seres Therapeutics's CUSIP number?
Seres Therapeutics's Committee on Uniform Securities Identification Procedures number is: 81750R102